Case Details
- Citation: [2011] SGHC 71
- Case Title: Martek Biosciences Corporation v Cargill International Trading Pte Ltd
- Court: High Court of the Republic of Singapore
- Date of Decision: 29 March 2011
- Judge: Tay Yong Kwang J
- Coram: Tay Yong Kwang J
- Case Number: Originating Summons No. 156 of 2010
- Tribunal/Body Below: Deputy Registrar of Patents and Principal Assistant Registrar of Patents (IPOS Tribunal)
- Decision Date Below: 31 December 2009
- Applicant/Plaintiff: Martek Biosciences Corporation
- Respondent/Defendant: Cargill International Trading Pte Ltd
- Legal Area: Patents and Inventions
- Procedural History: Appeal by Applicant against Tribunal’s decision in revocation proceedings; Respondent cross-appealed on aspects of Tribunal’s decision relating to amendments.
- Key Proceedings Below: (1) Revocation Proceedings; (2) Amendment Proceedings; heard together by Tribunal from 16 to 18 February 2009.
- Patent at Issue: Singapore Patent P-No. 49307, entitled “Microbial Oil Mixtures and Use Thereof”
- Patent Grant Date: 10 January 2002
- Application Date: 13 April 1996 (under s 116(6) of the Patents Act (Cap 221, 1995 Rev Ed))
- Amendments Filed: 1997 Amendments (2 July 1997); 1999 Amendments (13 October 1999); Proposed 2006 Amendments (filed with leave; advertised 30 October 2006); Proposed 2008 Amendments (filed 19 March 2008)
- Revocation Application Filed: 20 January 2006
- Grounds for Revocation (as pleaded): Not a patentable invention (s 80(1)(a)); insufficiency (s 80(1)(c)); added matter in amendments (s 80(1)(d)(i))
- Amendment Objections (as pleaded): Proposed 2006 Amendments allegedly extend beyond application as filed (s 84(3)(a)); Proposed 2008 Amendments objected on ground of extending protection
- Witnesses (Statutory Declarations): Respondent: Dr Puah Chum Mok; Dr Nga Been Hen. Applicant: Dr Eric Lien; Dr David Kyle.
- Notable Evidence Issue: Respondent withdrew Dr Puah from taking the stand, leaving his statutory declaration untested by cross-examination.
- Notable Evidence Issue: Tribunal treated Dr Nga’s evidence cautiously due to limited expertise in human dietary use and hindsight effects after reading the patent.
- Notable Evidence Issue: Tribunal scrutinised Applicant’s expert evidence with greater care due to increased likelihood of bias.
- Outcome (High Court): Applicant’s appeal allowed against Tribunal’s decision in revocation proceedings; both parties’ appeals/cross-appeals on amendment proceedings dismissed except regarding Claim 42 and consequently Claim 45 in the Proposed 2006 Amendments.
- Judgment Length: 19 pages, 10,185 words
- Counsel: Applicant: Dr Stanley Lai, SC and Mr Vignesh Vaerhn (Allen & Gledhill LLP). Respondent: Mr Daniel Koh (instructed) (Eldan Law LLP) and Ms Wendy Low Wei Ling (Rajah & Tann LLP).
Summary
Martek Biosciences Corporation v Cargill International Trading Pte Ltd [2011] SGHC 71 is a Singapore High Court decision arising from patent revocation and amendment proceedings before the IPOS Tribunal. The case concerns a Singapore patent for “Microbial Oil Mixtures and Use Thereof”, relating to compositions of microbial oils and their use—particularly as supplements for infant formula—to increase long chain polyunsaturated fatty acids (lcPUFAs) such as arachidonic acid (ARA) and docosahexaenoic acid (DHA).
The High Court (Tay Yong Kwang J) allowed the Applicant’s appeal against the Tribunal’s decision that the patent, as amended, should be revoked. The Court dismissed most of the parties’ challenges to the Tribunal’s handling of amendments, but it made a limited adjustment: it upheld the Tribunal’s approach except in relation to Claim 42 and, consequentially, Claim 45 in the Proposed 2006 Amendments. The decision is notable for its careful treatment of expert evidence, procedural fairness in cross-examination, and the sequencing of legal analysis between validity and amendment allowability.
What Were the Facts of This Case?
The Applicant, Martek Biosciences Corporation, is a Delaware-incorporated company. The Respondent, Cargill International Trading Pte Ltd, is incorporated in Singapore. Martek is the proprietor of Singapore Patent P-No. 49307, entitled “Microbial Oil Mixtures and Use Thereof”. The patent was applied for on 13 April 1996 and granted on 10 January 2002. The invention, as described in the abstract, focuses on microbial oil blends and methods of using such compositions, particularly as supplements for infant formula, with the aim of increasing the amount of long chain polyunsaturated fatty acids in infant formula.
From the outset, the patent prosecution involved multiple amendment stages. Two sets of amendments were filed prior to grant: the 1997 Amendments (dated 2 July 1997) and the 1999 Amendments (dated 13 October 1999). After grant, further amendments were proposed. On 20 January 2006, Cargill filed an application to revoke the patent. In response, Martek filed proposed amendments in 2006 (the Proposed 2006 Amendments) pursuant to section 83 of the Patents Act and the relevant Patents Rules. These were advertised in The Patents Journal on 30 October 2006, and during the allowable opposition period Cargill filed a notice of opposition alleging that the proposed amendments disclosed additional subject matter beyond what was originally disclosed in the application as filed.
Martek then obtained leave to file another set of amendments in 2008 (the Proposed 2008 Amendments), filed on 19 March 2008 and advertised on 28 May 2008. Cargill objected by letter dated 27 March 2008, contending that the amendments extended the protection conferred by the patent. In parallel, at a case management conference, IPOS Hearing Officers indicated an intention to re-examine the patent under section 80(2) of the Patents Act. Cargill requested re-examination, and an examiner from the Danish Patent and Trademark Office produced a re-examination report, made available to the parties on 6 January 2009.
Both the revocation proceedings and the amendment proceedings were consolidated and heard together by the Tribunal from 16 to 18 February 2009. The Tribunal’s decision, dated 31 December 2009, held in substance that the patent should be revoked: it found that the claims in the proposed amendments and the 1999 amendments were not patentable, while also addressing sufficiency and allowability issues under the Patents Act. Martek appealed to the High Court, and Cargill cross-appealed on aspects of the Tribunal’s amendment-related determinations.
What Were the Key Legal Issues?
The High Court had to determine, first, whether the Tribunal was correct in concluding that the patent (as amended) was not patentable and should therefore be revoked. The revocation application had pleaded multiple statutory grounds under the Patents Act, including that the invention was not a patentable invention (s 80(1)(a)), that the specification was insufficient (s 80(1)(c)), and that the 1999 Amendments disclosed matter beyond what was disclosed in the application as filed (s 80(1)(d)(i)). These grounds required the Court to assess both the technical disclosure and the legal boundaries of what could be claimed.
Second, the Court had to address the amendment proceedings. The Proposed 2006 and Proposed 2008 Amendments were challenged on allowability grounds, particularly whether they introduced additional subject matter beyond the original application as filed, and whether they improperly extended the protection conferred by the patent. The statutory framework for amendments required the Court to consider whether the amended claims met the requirements for allowability, including the prohibition on added matter. The High Court also had to consider the consequences of any findings on allowability for the scope of claims that would remain in force.
Third, and importantly in practice, the Court had to evaluate the evidential record, especially expert evidence provided via statutory declarations. The judgment highlights procedural fairness concerns where an expert who authored a statutory declaration was withdrawn from giving oral evidence and therefore could not be cross-examined. This evidential issue intersected with the substantive legal questions, because the Court’s assessment of novelty, inventive step, sufficiency, and added matter depends heavily on technical expert interpretation of the prior art and the patent specification.
How Did the Court Analyse the Issues?
At the outset, Tay Yong Kwang J adopted a structured approach to the legal analysis. Although the Tribunal had examined allowability of each amendment set before assessing validity, the High Court considered that a better approach was to first determine whether the patent is valid in principle, and only then to examine whether the respective sets of amendments are allowable. This sequencing matters because amendment allowability often depends on the content and scope of what is already validly claimed; conversely, if the core patent is not valid, amendment questions may become academic. The Court therefore proceeded to focus on validity as amended by the 1999 Amendments (save for Claim 30, which was not appealed by Cargill).
In dealing with validity, the Court applied the statutory grounds for revocation under the Patents Act. While the provided extract is truncated before the full articulation of the legal tests, the judgment clearly indicates that the Court considered the relevant statutory provisions on patentability, sufficiency, and added matter. The Court also addressed the prior art documents relied upon by Cargill, which were labelled D1 to D35 and T1 to T4 before the Tribunal. The parties focused particularly on D1, D2, D3, D27 and D34. These documents included European patent applications and scientific literature concerning omega-3 fatty acids, alternative sources, and clinical or experimental findings related to supplementation and infant outcomes.
A significant part of the Court’s analysis concerned the treatment of expert evidence. The Respondent’s witnesses included Dr Puah Chum Mok and Dr Nga Been Hen. A key procedural issue arose because Dr Puah was withdrawn from taking the stand, despite not withdrawing his statutory declaration. As a result, Martek did not have the opportunity to cross-examine Dr Puah on the content of his statutory declaration. The High Court treated this as “a significant issue” and addressed it later in the judgment. This reflects a fundamental evidential principle: where expert opinion is presented without the opportunity for cross-examination, the weight to be given to that evidence may be reduced, and the Court must be cautious in relying on it to make technical determinations that affect legal outcomes.
Similarly, the Court scrutinised Dr Nga’s evidence. Dr Nga admitted he was not an expert in the use of microbial oils in the human diet and lacked broad knowledge of general nutrition and paediatric nutrition. He also conceded that his conclusions on prior art documents were made with the benefit of hindsight after reading the patent. The Tribunal therefore held that it would be “cautious” about relying on his evidence. The High Court indicated that it would address the significance of these limitations. This is important because patent validity often turns on how a skilled person would understand prior art and the patent specification at the relevant date, and hindsight can distort that assessment.
On the Applicant’s side, the Court considered the evidence of Dr Eric Lien and Dr David Kyle. Dr Lien was a consultant to the Applicant and an expert in dietary fatty acids and infant formula research. The Respondent questioned his objectivity but did not challenge his testimony during cross-examination, leaving his evidence unchallenged. Dr Kyle, the sole inventor, had expertise in micro-organisms and PUFAs found in polar and non-polar lipids. The Tribunal accepted their testimonies where relevant to technical issues but scrutinised them with greater care due to increased likelihood of bias. The High Court’s approach suggests that it did not simply accept expert evidence at face value; rather, it evaluated credibility, expertise, and the procedural context in which evidence was produced.
Finally, the Court addressed amendment allowability and claim-specific issues. While the extract does not reproduce the full reasoning on each claim, it is clear that the High Court dismissed both parties’ appeals and cross-appeals against the Tribunal’s amendment-related decision except for Claim 42 and consequentially Claim 45 in the Proposed 2006 Amendments. This indicates that the Court found an error or misapplication of the legal test for allowability (or a related claim construction issue) limited to those claims. The narrow scope of the correction underscores that the High Court was not broadly overturning the Tribunal’s amendment framework; instead, it made a targeted adjustment to the claim set.
What Was the Outcome?
The High Court allowed the Applicant’s appeal against the Tribunal’s decision in the revocation proceedings. In practical terms, this means that the patent was not revoked on the grounds accepted by the Tribunal. The decision therefore preserves the patent’s enforceability, subject to the claim amendments that remain allowable.
On the amendment proceedings, the High Court dismissed both parties’ appeals and cross-appeals against the Tribunal’s decision, except with regard to Claim 42 and consequently Claim 45 in the Proposed 2006 Amendments. The effect is that the claim set was adjusted accordingly, while the remainder of the Tribunal’s amendment determinations stood.
Why Does This Case Matter?
Martek v Cargill is instructive for patent practitioners in Singapore because it demonstrates how the High Court approaches both substantive patent law and the evidential mechanics of patent litigation. First, it highlights the importance of expert evidence quality and procedural fairness. Where an expert’s statutory declaration is introduced without the opportunity for cross-examination, the Court may treat that as a significant evidential handicap. Practitioners should therefore consider carefully whether to withdraw an expert from the stand and the downstream consequences for evidential weight.
Second, the case illustrates the Court’s preference for a coherent analytical sequence: determining validity first (at least at the level of the relevant amended patent) before engaging in amendment allowability analysis. This sequencing can streamline litigation and avoid unnecessary disputes about amendments if the underlying patent is not valid. Conversely, if validity is upheld, amendment allowability becomes the mechanism for tailoring the scope of enforceable claims.
Third, the decision is a useful reference point on claim-level amendment disputes. The Court’s limited intervention—affecting Claim 42 and consequentially Claim 45—shows that appellate review in amendment matters can be granular. This is valuable for drafting and prosecution strategy: parties should focus amendment arguments on specific claim elements and ensure that any alleged added matter or extension of protection is tied to the precise claim language at issue.
Legislation Referenced
- Patents Act (Cap 221, 2005 Rev Ed) — sections 80(1)(a), 80(1)(c), 80(1)(d)(i), 80(2), 83, 84(3)(a), 116(6)
- Evidence Act — (referenced in the judgment context of statutory declarations and evidential treatment)
- Patents Rules (Cap 221, R1, 1996 Rev Ed) — rules 80(3), 81(1)(a), 85(1)
Cases Cited
- [2011] SGHC 71 (the present case)
Source Documents
This article analyses [2011] SGHC 71 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.